Is this you? Create Your Porfile
Avatar

Rudi Dr Gruetzmann

Bayer

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Rudi Dr Gruetzmann is active.

Explore More

Publication

Featured researches published by Rudi Dr Gruetzmann.

Archive | 1997

Heterocyclic-substituted phenylglycinolamides with antiatheroschlerotic activity and process for their production

Siegfried Goldmann; Ulrich Dr. Müller; Richard Connell; Hilmar Bischoff; Dirk Denzer; Rudi Dr Gruetzmann; Martin Dr. Beuck

Archive | 1997

Benzyloxy-substituted phenylglycinolamides as pharmaceutical agents

Siegfried Goldmann; Ulrich Dr. Müller; Richard Connell; Hilmar Bischoff; Dirk Denzer; Rudi Dr Gruetzmann; Martin Dr. Beuck

Archive | 1997

Pyridazino-, pyrimido, pyrazino and triazino-indoles

Hilmar Bischoff; Dirk Denzer; Peter Eckenberg; Rudi Dr Gruetzmann; Ulrich Dr. Müller; Ulrich Nielsch

Archive | 1999

New pyridoindolylmethyl-phenylacetic acid amide derivatives useful in lowering serum cholesterol levels in treatment of e.g. atherosclerosis, coronary heart disease, apoplexy and thromboses

Ulrich Dr Mueller; Hans-Juergen Ploschke; Rudi Dr Gruetzmann; Wolfgang Kanhai

Archive | 1997

Heterocyclic aryl-, alkyl- and cycloalkylacetic acid amides

Richard Connell; Siegfried Goldmann; Ulrich Dr Mueller; Martin Dr. Beuck; Hilmar Bischoff; Dirk Denzer; Rudi Dr Gruetzmann; Stefan Wohlfeil

Archive | 1996

Amides and sulfonamides of benzylamines with heterocyclic substituents

Ulrich Dr Mueller; Richard Connell; Hilmar Bischoff; Dirk Denzer; Stefan Lohmer; Stefan Wohlfeil; Rudi Dr Gruetzmann

Archive | 1991

Use of efomycins a, e and g as antiinflammatory agents

Hartwig Mueller; Erwin Bischoff; Burkhard Fugmann; Karlheinz Weber; Klaus Frobel; Bruno Rosen; Rudi Dr Gruetzmann; Guenther Karmann; Christian Kohlsdorfer

Archive | 1999

Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and metabolically active drug

Rudi Dr Gruetzmann; Ulrich Dr Mueller

Archive | 2001

Utilisation d'inhibiteurs de proteine de transfert de triglycerides microsomale (mtp) pour abaisser les particules de lipoproteine a forte teneur en triglycerides postprandiaux

Rudi Dr Gruetzmann; Ulrich Mueller; Hilmar Bischoff; Siegfried Zaiss

Archive | 2000

Verwendung von MTP-Inhibitoren zur Senkung von ppTRL Use of MTP inhibitors to reduce ppTRL

Rudi Dr Gruetzmann; Ulrich Dr Mueller; Hilmar Bischoff; Siegfried Zaiss

Explore More

Collaboration

Dive into the Rudi Dr Gruetzmann's collaboration.

Top Co-Authors
Avatar

Dirk Denzer

Bayer

View shared research outputs
Top Co-Authors
Avatar

Hilmar Bischoff

Bayer

View shared research outputs
Top Co-Authors
Avatar

Ulrich Dr Mueller

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors
Avatar

Siegfried Goldmann

Bayer

View shared research outputs
Top Co-Authors
Avatar

Martin Dr. Beuck

Bayer

View shared research outputs
Top Co-Authors
Avatar

Stefan Wohlfeil

Bayer

View shared research outputs
Top Co-Authors
Avatar

Richard Connell

Bayer

View shared research outputs
Top Co-Authors
Avatar

Stefan Lohmer

Bayer

View shared research outputs
Top Co-Authors
Avatar

Anke Domdey-Bette

Bayer

View shared research outputs
Top Co-Authors
Avatar

Richard D. Connell

Bayer Corporation

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge